Definitions of Stage D heart failure and outcomes among outpatients with heart failure and reduced ejection fraction
Related Experiment Video
Updated: Feb 6, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Jeffrey S Hedley1, Ayman Samman-Tahhan2, Andrew A McCue3
1Division of Cardiology, Cleveland Clinic, Cleveland, OH, United States of America.
Insights
Defining advanced heart failure (Stage D) is crucial. INTERMACS profiles offer a practical method for identifying Stage D heart failure (HF) in outpatients, outperforming other criteria in predicting outcomes.
Area of Science:
- Cardiology
- Heart Failure Research
- Clinical Outcomes
Background:
- A clear, operational definition for Stage D heart failure (HF) is currently absent.
- This study addresses the need for a consensus definition in clinical practice.
Purpose of the Study:
- To evaluate and compare three different definitions for Stage D heart failure (HF) in outpatients with reduced ejection fraction.
- To determine which definition best predicts mortality and other adverse outcomes.
Main Methods:
- 512 outpatients with systolic HF (ejection fraction ≤40%) were assessed.
- Three definitions were applied: physician designation, INTERMACS profiles (2-6), and ESC-HFA criteria.
- Patient outcomes, including mortality and hospitalization, were tracked over a median of 3.1 years.
Main Results:
- Physician designation, INTERMACS profiles, and ESC-HFA criteria identified 12.5%, 18.2%, and 13.1% of patients as Stage D, respectively, with modest agreement.
- The INTERMACS-based definition showed the best prognostic separation for 3-year mortality (HR 3.28) and hospitalization risk.
- Physician designation (HR 3.17) and ESC-HFA criteria (HR 2.02) also predicted outcomes, but less effectively than INTERMACS profiles.
Conclusions:
- INTERMACS profiles provide a practical and effective tool for identifying Stage D HF in ambulatory patients with systolic dysfunction.
- The European Society of Cardiology Heart Failure Association (ESC-HFA) criteria demonstrated limited prognostic value in this cohort.
Background:
An operational consensus definition of Stage D heart failure (HF) is currently lacking.
Methods:
We evaluated 512 outpatients (median age, 63 years; 35.0% women; 45.5% white and 45.9% black; median ejection fraction was 25%; 67.4% had coronary artery disease) with HF and reduced (≤40%) ejection fraction. We applied 3 hypothetical definitions for Stage D: (1) designation as "Stage D" or "advanced" HF by treating physician; (2) INTERMACS profiles, defining Stage D as profiles 2-6; and (3) European Society of Cardiology Heart Failure Association (ESC-HFA) criteria.
Results:
Physicians, INTERMACS profiles, and ESC-HFA criteria identified 64 (12.5%), 93 (18.2%), and 67 (13.1%) patients, respectively, as Stage D, with modest concordance between definitions (κ = 0.37). After a median of 3.1 years, 97 patients died (3-year mortality 20.4%). Among patients identified as Stage D by physicians, 3-year mortality was 43.7% vs. 17.0% for non-Stage D patients (age-adjusted hazard ratio [HR] 3.17; 95%CI 1.94-5.18; P < 0.001). The corresponding mortalities for the INTERMACS-based definition were 41.0% vs. 16.2% (HR 3.28; 95%CI 2.11-5.11; P < 0.001) and for ESC-HFA criteria 33.5% vs. 18.6% (HR 2.02; 95%CI 1.22-3.33; P = 0.006); the INTERMACS-based definition provided the best prognostic separation. Results were similar with an alternative INTERMACS-based definition considering only profiles 2-5 as Stage D HF. The INTERMACS-based definition best separated all-cause and HF-specific hospitalization and composite endpoint risk between Stage D and non-Stage D patients also.
Conclusions:
INTERMACS profiles provide a practical alternative for the identification of Stage D HF in ambulatory populations with systolic HF. The ESC-HFA criteria offer limited prognostic information.
Related Concept Videos
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Heart Failure I: Introduction
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Diuretics
Heart Failure V: Medical Management

